Linalool

Other Names

(R)-Linalool(S)-Linalol(S)-Linalool1,6-Octadien-3-ol, 3,7-dimethyl-2,6-Dimethyl-2,7-octadien-6-ol2,6-Dimethyl-2,7-octadiene-6-ol2,6-Dimethylocta-2,7-dien-6-ol3,7-Dimethyl-1,6-octadien-3-ol3,7-Dimethyl-1,6-octandien-3-ol3,7-Dimethylocta-1,6-dien-3-ol3,7-Dimethylocta-1,6-dien-3-ol (IUPAC)Allo-ocimenolb-Linaloolbeta-LinaloolCoriandroldl-3,7-Dimethyl-3-hydroxy-1,6-octadienedl-LinaloolL-LinaloolLicareolLinalolLinalool BLinaloyl oxideLinalyl alcoholLinanoolLinoloolNSC 3789p-LinaloolR/S-Linaloolβ-Linalool

Synopsis

Linalool: A Comprehensive Reference

1. Identity and Chemical Characterization

Nomenclature

Linalool, also called linalol, is either of two enantiomers of a naturally occurring terpene alcohol found in many flowers and spice plants. Other chemical names include 2,6-dimethylocta-2,7-dien-6-ol; β-linalool; linalyl alcohol; linaloyl oxide; p-linalool; allo-ocimenol; and 3,7-dimethyl-1,6-octadien-3-ol. Its CAS registry number is 78-70-6. The word linalool is based on linaloe, a type of wood, and the suffix -ol.

Physical and Chemical Properties

Linalool is a colorless oil classified chemically as an acyclic monoterpene alcohol. Its molecular formula is C₁₀H₁₈O. Its classification as a monoterpene means its core carbon skeleton is formed from two linked five-carbon isoprene units. The presence of the hydroxyl functional group (–OH) makes linalool a tertiary alcohol, which contributes to its chemical reactivity and volatility. It appears as a clear, colorless liquid with a boiling point of 198–199 °C and a density of 0.8622–0.870 g/cm³, exhibiting moderate solubility in water (1,590 mg/L at 25 °C) and high solubility in organic solvents such as alcohol, ether, and fixed oils.

Stereochemistry: Two Enantiomers

Linalool has a stereogenic center at C3 and therefore exists as two stereoisomers: (R)-(−)-linalool, also known as licareol, and (S)-(+)-linalool, also known as coriandrol. Each enantiomer evokes distinct neural responses in humans, so each is classified as possessing distinct scents. The (R)-linalool isomer is typically associated with a more woody and lavender-like aroma and is the dominant form found in lavender and sweet basil. Conversely, the (S)-linalool isomer is perceived as sweet, floral, and petitgrain-like, being the primary component in plants like coriander and sweet orange flowers.

Biosynthesis

The biosynthesis of linalool involves intricate metabolic pathways within plants, where it is naturally produced as part of the plant's defense mechanisms and for attracting pollinators. This process is primarily facilitated by terpene synthases (TPSs), which are the vital terminal enzymes catalyzing the formation of monoterpene linalool using geranyl diphosphate (GPP) as a substrate.

2. Natural Sources and Botanical Distribution

Linalool is produced by over 200 species of plants, including those from the mint (Lamiaceae), laurel (Lauraceae), and citrus (Rutaceae) families. It is a major component in the essential oils of commercially important plants such as lavender, rosewood, and basil. Linalool is also found in essential oils of coriander (Coriandrum sativum) seed, palmarosa (Cymbopogon martinii var. martini), sweet orange (C. sinensis) flowers, lavender (Lavandula officinalis), bay laurel (Laurus nobilis), and sweet basil (Ocimum basilicum).

(S)-linalool is found, for example, as a major constituent of the essential oils of coriander (Coriandrum sativum L.), cymbopogon (Cymbopogon martini var. martinii), and sweet orange (Citrus sinensis) flowers; (R)-linalool is present in lavender (Lavandula officinalis), bay laurel (Laurus nobilis), and sweet basil (Ocimum basilicum), among others.

In plants, linalool is a metabolite, a volatile oil component, an antimicrobial agent, and an aroma compound. Annually, approximately 1,000 metric tons of linalool are consumed globally each year.

Common Forms and Preparations

Linalool is widely found in essential oils and is broadly used in perfumes, cosmetics, household cleaners, and food additives. In commerce, it is encountered primarily in the following forms:

Essential oils: Linalool is a major or significant constituent of lavender, coriander, basil, rosewood, palmarosa, and ho-leaf oils, and is delivered topically, by inhalation/aromatherapy, or in food preparations in this form.
Isolated/purified monoterpene: Linalool (C₁₀H₁₈O), so-called 3,7-dimethyl-1,6-octadien-3-ol, is a monoterpene alcohol broadly present as a major constituent of plant essential oils, particularly lavender and coriander. It can be extracted and used in isolated form as a flavoring or fragrance ingredient.
Oral capsules (Silexan): A standardized lavender oil preparation (Silexan) containing a defined linalool content is available as an oral soft-gel capsule, used in clinical trials and marketed in Europe for anxiety.
Synthetic linalool: Large-scale commercial production also involves synthetic synthesis routes to meet industrial fragrance and flavor demand.
Linalyl acetate: Linalool exists in nature in two closely related forms: its primary terpene structure and a naturally occurring variation called linalyl acetate. These two versions often show up together in the same plants, contributing to the layered, complex aromas associated with lavender, citrus, and certain cannabis strains.

3. Traditional and Historical Use

The medicinal properties of essential oils from aromatic plants are known since antiquity. Technological innovation has since enabled the reinvention of this ancient plant knowledge by enabling identification and extraction of organic compounds present in essential oils. These organic compounds belong mainly to the terpene group and are accountable for the wide range of bioactive properties attributed to essential oils.

Across many cultures, plants containing linalool have played meaningful roles in traditional herbal practices. In places like China, India, Egypt, and Rome, botanicals such as lavender, coriander, and rosewood were commonly incorporated into daily rituals, wellness traditions, and aromatic preparations. These plants were often valued for their pleasant scents and their place in cultural practices that supported relaxation, rest, or general well-being. Different regions used these aromatic plants in their own ways—burned as incense, blended into oils, added to baths, or included in herbal mixtures.

Linalool is present in a number of fragrant plant species, many of which are employed as analgesics and anti-inflammatory medicines in traditional medicine. In Ayurvedic, traditional Chinese, and Middle Eastern healing systems, linalool-rich plants such as lavender and coriander have been used for purposes ranging from calming nervous agitation and promoting sleep to alleviating headaches, digestive complaints, and skin irritations. However, historical records document the use of these plants rather than the isolated compound, as the chemical identity of linalool was not established until later.

The discovery and industrial production of linalool have a rich historical background, intertwined with the evolution of perfumery and the understanding of essential oils. Initially produced in 1875 by isolation from Cayenne Bois de Rose oil, linalool was later sourced from various plants like linaloe and ho-leaf oils.

4. Key Constituents and Mechanisms of Action

Linalool itself is both the active compound of interest and a constituent within complex essential oil matrices. Its pharmacological activities are attributed to several identified molecular mechanisms, though it must be noted that most mechanistic research has been conducted in preclinical (animal and cell-based) models, and human mechanistic data remain limited.

GABAergic Modulation

Various monoterpenoids, including the acyclic linalool, enhance GABAergic currents in an allosteric manner in vitro upon overexpression of inhibitory α1β2 GABA_A receptors in various expression systems. In animal studies, linalool odor-induced anxiolytic effects were not observed in anosmic mice, indicating that the effect was triggered by olfactory input. The effect was antagonized by flumazenil, indicating that the linalool odor-induced anxiolytic effect was mediated by γ-aminobutyric acid (GABA)ergic transmission via benzodiazepine (BDZ)-responsive GABA_A receptors.

However, the mechanistic picture is not fully settled. Data from one rat study suggest that linalool does not produce anxiolysis by modulation of the GABA_A receptor; however, linalool may modulate motor movements and locomotion. In plants or humans, following intake via inhalation or ingestion, linalool undergoes metabolic modifications including oxygenation and acetylation, which may affect the modulatory efficacy of generated linalool derivatives.

Glutamatergic (NMDA) Inhibition

Using electrophysiological measurements, a non-selective suppression of voltage-gated sodium channels has been demonstrated in olfactory receptor neurons and Purkinje cells. Furthermore, linalool suppressed the function of excitatory glutamate receptors. Linalool was shown to inhibit the K⁺-stimulated glutamate release and glutamate uptake by mouse cortical synaptosomes. In addition, it displayed the ability to inhibit the binding of MK801, an NMDA antagonist with anticonvulsant properties, in a concentration-dependent manner. Together these findings suggest the ability of linalool to block NMDA receptors in vitro and in vivo, even if further investigations are needed to confirm this mechanism.

Antioxidant and ROS Scavenging

Linalool is a reducing agent due to its ability to scavenge reactive oxygen species (ROS) and to stimulate other antioxidants from their inactive state. Research in animal models found that linalool suppressed ROS production and inflammatory response induced by amyloid-β expression and reduced neurodegeneration. These results are consistent with previous studies showing that linalool has antioxidant and anti-inflammatory properties in mouse models and in vitro assays, which suggests that these properties are the main mechanisms underlying the neuroprotective effect of linalool.

Anti-Inflammatory Pathways

Linalool demonstrates anti-inflammatory action in various in vivo and in vitro studies, including in UVB-activated Human Dermal Fibroblasts adult (HDFa) skin cells, lipopolysaccharide (LPS)-stimulated H292 airway epithelial cells, and ovalbumin-induced airway hyperresponsiveness.

Antimicrobial Mechanisms

Reduction in membrane potential, leakage of alkaline phosphatase, and the release of macromolecules including DNA, RNA, and protein confirmed that damage to cell wall membrane structure and leakage of cytoplasmic contents occur following linalool treatment. The decrease of enzyme activity including succinate dehydrogenase, malate dehydrogenase, pyruvate kinase, and ATPase indicates that linalool can lead to metabolic dysfunction and inhibit energy synthesis. In addition, linalool inhibits cellular respiration.

In Pseudomonas aeruginosa, linalool disrupts cell membrane integrity and interferes with the respiratory chain, leading to cell death. In Escherichia coli, linalool binds to plasmid DNA and alters its structure, reducing plasmid transfer between strains and thereby decreasing the spread of resistance. Linalool can inhibit the formation of various microbial biofilms by disrupting quorum sensing systems or inhibiting hyphal formation.

Anticancer Pathways

Linalool exerts significant actions in human oral cancer cells by prompting cell apoptosis and diminishing the phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT) signaling pathway. Linalool is a promising anticancer agent for hepatocellular carcinoma (HCC) therapy via inducing cell apoptosis via Ras, Mitogen-activated protein kinase (MAPKs), and the AKT/mTOR pathways. These findings derive from cell culture and animal models; no human clinical trials on linalool as an anticancer agent have been completed.

Blood-Brain Barrier Penetration

Linalool is a constituent of several essential oils derived from plants including lavender and cardamom. Its high lipophilicity and low molecular weight allow it to pass through the blood–brain barrier. As a result, it can be utilized in the pharmacological management of cognitive and behavioral abnormalities.

5. Scientific Evidence by Area of Use

5.1 Anxiety and Stress

Preclinical Evidence

A physiological effect on sedation and anxiety-related behavior has been shown in several animal studies following inhalation of linalool, with comprehensive analysis of mice in relation to anxiety-related behavior, social interactions, and aggression behavior. Results from a study using the open-field, swings box, hole-crossing, and dark-resident time tests showed that linalool and sesamol individually have significant anxiolytic-like activity in mice.

Linalool in ambient air decreased mouse motility by 73%, confirming its potent sedative effects.

Human and Clinical Evidence

The most robust human evidence for the anxiolytic effects of linalool comes from research on standardized lavender oil preparations where linalool is a primary identified constituent. The main constituents of lavender essential oil are linalool, linalyl acetate, 1,8-cineole, β-ocimene, terpinen-4-ol, and camphor. The key active constituents are linalyl acetate and linalool, which are responsible for the calming and sedative effects of lavender and are also the major constituents of L. angustifolia.

A systematic review comprising 11 studies with 972 participants found that 10 reported significantly decreased anxiety levels after lavender oil inhalation. The review showed that lavender inhalation had a significant anxiety-reducing effect on both the psychological and physiological manifestations of anxiety.

A triple-blind, randomized controlled trial comparing effects of lavender and bitter orange on anxiety in 156 postmenopausal women found Spielberger's State-Trait Anxiety Inventory scores were statistically significantly improved with lavender compared to placebo. Lavender capsules in this study contained 500 mg of whole dried herb (linalool 36.12%, linalyl acetate 26.32%, caryophyllene 7.55%).

The safety and efficacy of Silexan 80 mg daily each morning in adults with mixed anxiety and depressive disorder (MADD) were investigated in a double-blind, randomized, placebo-controlled, multicenter trial (N=318). Five studies were identified with a total of 524 participants receiving treatment with Silexan 80 mg and 121 participants taking Silexan 160 mg in a network meta-analysis assessing anxiolytic effects against comparators including placebo, paroxetine, and lorazepam.

In a study of 30 healthy men, inhalation of lavender was associated with a reduction in serum cortisol levels (from 8.4 ± 3.6 mg/dL to 6.3 ± 3.3 mg/dL; P<0.05) following aromatherapy.

Evidence strength: For anxiety, evidence via lavender oil preparations (in which linalool is a major constituent) is moderately strong, with multiple randomized controlled trials (RCTs) and systematic reviews. However, most studies do not isolate the effects of pure linalool from those of the whole essential oil matrix; attributing outcomes solely to linalool requires caution.

5.2 Sleep

In a randomized, placebo-controlled crossover study, data from 37 adults with type 2 diabetes showed significant improvements in Beck Depression Inventory scores, sleep quality, and quality of life with lavender oil aromatherapy inhaled 5 minutes before bedtime for 4 weeks compared to sweet almond oil control.

A 2025 randomized controlled trial found that lavender essential oil (LEO) inhalation aromatherapy could effectively improve postoperative sleep quality, particularly on the fourth postoperative day, and also positively impacted anxiety and reduced the duration of postoperative delirium. The primary bioactive constituents (linalool and linalyl acetate) may enhance perioperative sleep quality by entering the circulatory system through inhalation and modulating the GABAergic, cholinergic, histaminergic, and monoaminergic pathways in the limbic system.

Evidence strength: Preliminary to moderate. Multiple small-to-medium RCTs support sleep-quality benefits from linalool-containing lavender aromatherapy, but pure linalool has not been isolated as the sole variable in human sleep research.

5.3 Antimicrobial Activity

Linalool exhibits antibacterial activity against Staphylococcus aureus NCTC 10788, Pseudomonas aeruginosa NCTC 12924, and Escherichia coli NCTC 12923. Previous studies have shown that linalool is important due to its broad spectrum of biological activities including antioxidant, anti-inflammatory, anticancer, cardioprotective, and antimicrobial activities. Among opportunistic hospital strains, it is most active against Gram-negative bacteria.

Linalool showed significant anti-biofilm activity through both dispersal and killing of cells in the biofilm based on confocal scanning laser microscopy and SEM imaging, crystal violet staining, XTT and COMSTAT assays.

Linalool has been shown to have antimicrobial activity when used alone and can also be used as an adjunct antimicrobial agent to increase antibiotic sensitivity.

Evidence strength: Evidence is primarily in vitro (cell culture) and in animal/food-preservation models. Minimum inhibitory concentration (MIC) values have been established for various pathogens. Controlled human clinical trials examining linalool as an anti-infective agent in humans are lacking.

5.4 Analgesic and Local Anesthetic Effects

The local anesthetic effects of linalool are reported to be equal to those of procaine and menthol in preclinical studies. Another explanation would be its ability to produce hot-plate analgesia in mice (P<0.001) that was reduced by administration of an adenosine A2A antagonist.

Due to its antioxidant properties, linalool proved to be neuroprotective against excitotoxicity as it reduced oxidative stress and mitochondrial dysfunction in hippocampal slices exposed to NMDA and in HT-22 cells exposed to glutamate, displaying the potential to serve as a multi-target therapeutic agent.

Evidence strength: Analgesic and local anesthetic properties are well established in preclinical rodent models. Human data are absent for linalool used as a pure compound; clinical reports relate to preparations containing linalool as one of many constituents.

5.5 Anticonvulsant Effects

Anticonvulsant activity has been reported for the seeds and leaves of coriander. Furthermore, linalool as the main component of coriander has different neuropharmacological effects, including anti-anxiety, sedative, anticonvulsant, and anti-Alzheimer's disease activities.

Both the essential oil and hydroalcoholic extract of lavender have shown protective effects in a model of PTZ-induced seizures, where they significantly increased seizure latency and survival percentage, although the exact mechanisms were not identified.

Evidence strength: All anticonvulsant evidence is preclinical (animal models). No human clinical trials specifically investigating linalool's anticonvulsant properties have been conducted.

5.6 Neuroprotective Effects and Alzheimer's Disease

Although several studies have shown the beneficial effect of linalool in Alzheimer's disease (AD) animal models, the underlying mechanisms have not been fully elucidated. In one study, linalool intake increased the survival of AD model flies during development in a dose-dependent manner, while the survival of wild-type flies was not affected even at high concentrations. Linalool also decreases Aβ-induced apoptosis in eye discs and the larval brain, and was found to reduce neurodegeneration in the brain of adult AD model flies. However, linalool did not affect the total amount of Aβ42 protein or Aβ42 aggregation.

Several studies have shown that linalool exerts a neuroprotective effect by inhibiting inflammation in vitro and in vivo. Linalool also protects neurons by decreasing ROS levels in patients with carpal tunnel syndrome, which is a ROS-induced peripheral neuropathy. This represents one of the rare instances where a linalool-relevant human observation has been reported in a clinical context, though carpal tunnel syndrome studies used complex preparations rather than isolated linalool.

Evidence strength: Predominantly preclinical. Animal (Drosophila, rodent) and in vitro models show consistent neuroprotective effects. No human clinical trials exist specifically testing isolated linalool in neurodegenerative disease.

5.7 Anticancer Activity

The cytotoxic effect of linalool on human cancer cell lines has been investigated. Water-soluble tetrazolium salts (WST-1) based colorimetric cellular cytotoxicity assay was used to test the cytotoxic ability of linalool against U937 (leukemia) and HeLa (cervical) cells, and flow cytometry and genechip analysis were used to investigate the possible mechanism of apoptosis.

Linalool retains anticancer effects. It exerts significant actions in human oral cancer cells by prompting cell apoptosis and diminishing the PI3K/AKT signaling pathway. Linalool is a promising anticancer agent for hepatocellular carcinoma therapy via inducing cell apoptosis via Ras, MAPKs, and the AKT/mTOR pathways.

Evidence strength: Entirely preclinical. Anticancer evidence is restricted to in vitro cell lines and animal studies. No human clinical trials on linalool as an anticancer therapeutic have been reported.

5.8 Anti-Inflammatory Activity

Linalool has a range of biological properties including sedative, anxiolytic, anticonvulsant, anesthetic, analgesic, anti-inflammatory, antioxidant, and antimicrobial activities. Anti-inflammatory investigations have focused on inhibition of pro-inflammatory mediators. Linalool demonstrates anti-inflammatory action in various in vivo and in vitro studies, including in UVB-activated Human Dermal Fibroblasts adult (HDFa) skin cells and in LPS-stimulated H292 airway epithelial cells.

Evidence strength: In vitro and animal model data are consistent and mechanistically plausible, but human anti-inflammatory trials isolating linalool specifically are lacking.

6. Body Systems and Health Areas Associated with Linalool

Central Nervous System: Anxiolytic and sedative effects; anticonvulsant properties; neuroprotection against amyloid-β toxicity, glutamate excitotoxicity, and cadmium-induced neurodegeneration.
Immune and Inflammatory System: Inhibition of pro-inflammatory cytokine pathways; demonstrated anti-inflammatory activity in skin, airway, and systemic models.
Oncology (Preclinical): Induction of apoptosis in multiple cancer cell lines via PI3K/AKT and MAPK signaling.
Microbiology / Infectious Disease: Broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria; anti-biofilm activity; potential adjunct to antibiotic therapy.
Peripheral Nervous System: Local anesthetic effects comparable to procaine in animal studies; adenosine A2A receptor-dependent analgesia.
Hepatic and Renal Systems: Linalool's bioactive properties include hepatoprotective and renal protective activity, reported in animal model studies.
Skin: Anti-inflammatory effects on skin cells; cosmetic applications; risk of contact sensitization via oxidized forms (see Safety section).

7. Dosage Forms and Reported Dosages

Dosages reported in identified sources are summarized below. These are figures from the cited studies and not clinical recommendations:

Oral lavender oil capsules (Silexan): Oral lavender supplementation at lavendula oil 80 to 160 mg/day was used in a case series of 8 adults with major depressive disorder (MDD) added to usual treatment. Silexan 80 mg daily was the dose investigated in a double-blind, randomized, placebo-controlled, multicenter trial (N=318) for mixed anxiety and depressive disorder.
Inhalation / aromatherapy: In one RCT, five drops of 10% lavender essential oil were applied to the cotton pad of a nasal patch positioned near the nasolabial fold, administered nightly for seven consecutive days following surgery, from 20:00 to 08:00. The lavender oil used in that trial was characterized as containing linalyl acetate (34.50%), linalool (27.85%), and lavandulol acetate (10.74%).
Animal/preclinical inhalation: Mice were placed in an inhalation apparatus for 60 minutes in an environment comprising either 1% or 3% linalool in studies of sedative/anxiolytic effects.
Animal/preclinical oral dosing: Tested chemicals at single-dose linalool (50 mg/kg) were administered orally to mice to conduct behavioral tests including open-field, swings box, hole-crossing, and dark-resident time tests.
Dietary/food exposure: The estimated human intake from the FEMA evaluation for lavender oil is 810 μg/person per day.

8. Safety Considerations and Regulatory Status

General Recognized Safety Status

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) concluded that linalool does not present a safety concern at current levels of intake when used as a flavoring agent. The Flavor and Extract Manufacturers Association (FEMA) Expert Panel has reviewed the safety of linalool and determined that it is Generally Recognized as Safe (GRAS) for use as a flavoring substance. Linalool is usually used as a food additive and is considered to be Generally Recognized as Safe (GRAS).

The safety of linalool is attested by the fact that it has been approved as a food flavoring by the European Commission.

Oxidation and Contact Allergy: A Key Safety Concern

Linalool is an unsaturated hydrocarbon and is therefore susceptible to oxidation in the presence of air. In its pure, fresh form, linalool is a weak skin allergen. But when exposed to air, it slowly oxidizes, and those oxidation products are potent skin sensitizers. Over a 10-week period, air-exposed linalool undergoes roughly 20% degradation, forming compounds called hydroperoxides that can trigger allergic contact dermatitis.

Patch testing studies have found that oxidized linalool products cause positive allergic reactions in 3.9% to 11.7% of people tested. The reactions are dose-dependent and have been confirmed through both standard patch testing and simulated real-world use conditions.

Clinical studies show that the exposure to allergens formed due to autoxidation causes significant contact allergy in consumers. Patch testing with oxidized limonene and oxidized linalool shows that these substances rank among the most common contact allergens.

Linalool and linalyl acetate are fragrance substances of clinical importance known to be prehaptens and to form sensitizing compounds by air oxidation.

European Regulatory Labeling Requirements

The EU requires cosmetic products to list linalool on their ingredient labels when it exceeds 0.001% in leave-on products (like lotions) or 0.01% in rinse-off products (like shampoos). Linalool (CAS no. 78-70-6) is one of 26 fragrances listed in Annex III of European cosmetics regulation, requiring mandatory labeling at these thresholds.

Metabolism and Accumulation

For the major components linalyl acetate and linalool, the available data in laboratory animals and humans indicate that they are absorbed, metabolized by oxidation and excreted, and are not expected to accumulate in animal tissues and products.

Drug Interactions: CYP Enzyme Involvement

This terpene can also influence CYP enzymes in rat liver, suggesting that it can alter the pharmacokinetics of co-administered substances. The extent and clinical significance of these interactions in humans have not been systematically studied.

High-Dose Toxicology (Animal Data)

Strain-dependent toxicity was seen in rats receiving multiple doses of 0.25 to 4 g/kg of linalool via skin absorption. Wistar rats receiving this regimen for 29 days lost weight and experienced discomfort, piloerection, lethargy, and ataxia. Clinical chemistry tests showed dose-related increases in alkaline phosphatase and increased glucose and cholesterol at the 4 g/kg dose. These doses are orders of magnitude greater than typical human dietary or aromatic exposures.

Safety in Cosmetic Re-evaluation

In 2015, the FEMA Expert Panel initiated a program for the re-evaluation of the safety of over 250 natural flavor complexes (NFCs) used as flavor ingredients. This re-evaluation evaluated the safety of NFCs containing linalool and/or other characteristic mono- and sesquiterpenoid tertiary alcohols and esters.

9. Summary of Evidence Landscape

Many clinical trials have been conducted to assess the potential properties of linalool-containing preparations; however, obtained results remain controversial. Across the literature, a consistent gradient in evidence quality is observed:

Strongest evidence (multiple RCTs + systematic reviews): Anxiolytic and sleep-promoting effects of lavender-derived preparations containing linalool as a principal active component, particularly via inhalation aromatherapy and the standardized oral preparation Silexan.
Moderate preclinical evidence with no human trials: Analgesic, local anesthetic, anticonvulsant, anti-inflammatory, and antioxidant effects.
Early-stage (in vitro/animal only): Anticancer, antimicrobial (as standalone treatment), and hepatorenal protective effects.
Well-established safety concern: Contact sensitization via autoxidized linalool hydroperoxides in cosmetic and fragrance products.

The molecular mechanisms behind linalool's actions as an anxiolytic agent remain unsolved. Rigorous human clinical trials isolating the pharmacological effects of purified linalool as a single compound—independent of complex essential oil matrices—are largely absent from the literature as of the time of this writing.

References

Health Conditions

Health conditions that Linalool may help support.

No conditions available.

Body Systems

Body systems that Linalool may help support.

No body systems available.